South Africa’s first consignment of lenacapavir, a six-monthly HIV prevention injection for high-risk HIV-negative people, will cover fewer than a quarter of the target population. Deliveries are underway and will continue through April. Rollout will begin immediately after delivery, with an initial two-year implementation plan. Lenacapavir has been described as an HIV game-changer because trial outcomes show it is close…